Posted by Michael Wonder on 31 Mar 2021
NICE recommends Sobi’s Kineret for first-line use in Still’s disease
31 March 2021 - NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis in people aged eight months or over with a body weight of 10 kg or more, who have not responded to at least one conventional disease modifying anti-rheumatic drug (DMARD).
The biologic therapy is also recommended for use in patients with adult onset Still’s disease who have responded inadequately to two or more conventional DMARDs.
